UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050450
Receipt number R000057442
Scientific Title Verification test of blood glucose level fluctuation by intake of test food
Date of disclosure of the study information 2023/06/30
Last modified on 2023/08/22 11:56:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification test of blood glucose level fluctuation by intake of test food

Acronym

Verification test of blood glucose level fluctuation by intake of test food

Scientific Title

Verification test of blood glucose level fluctuation by intake of test food

Scientific Title:Acronym

Verification test of blood glucose level fluctuation by intake of test food

Region

Japan


Condition

Condition

N/A

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this test is to examine the effect of ingestion of the test food on blood glucose level fluctuation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood glucose levels

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Single ingestion of test food-washout period-single ingestion of placebo food.

Interventions/Control_2

Single ingestion of placebo food-washout period-single ingestion of test food.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

40 years-old >

Gender

Male and Female

Key inclusion criteria

1) Healthy males and females aged 20 - 39 years.
2) Individuals who are healthy and are not suffered from a chronic malady.
3) Individuals who are able to come to the clinic and take the examination on the specified day.
4) Individuals who are fully informed about this study, have the ability to agree, participate voluntarily with good understanding, and agree informed consent in writing.
4) Individuals who can visit an inspection facility and be inspected in designated days.
5) Individuals who can draw blood from a fingertip.
6) Individuals judged appropriate for this study by the principal investigator.

Key exclusion criteria

1) Individuals using medical products.
2) Individuals who used a drug for treatment of disease in the past 1 month.
3) Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease.
4) Individuals who contract or have a history of serious gastrointestinal disease.
5) Individuals with serious anemia.
6) Individuals who contract or have a history of food allergy. (milk, gelatin)
7) Females who are or are possibly pregnant, or are lactating.
8) Individuals who have an addiction to alcohol or a mental illness.
9) Individuals who are a smoker.
10) Individuals with high blood glucose (fasting blood glucose over 110 mg/dL).
11) Individuals whose life style will change during the test period.
12) Individuals with probable seasonal allergy, such as pollinosis, during the test period.(Betulaceae: alder, oba alnus firma, shirakaba, Taxodiaceae: cryptomeria, hinoki cypress, Asteraceae: ragweed, Artemisia vulgaris indica, Gramineae:Dactylis glomerata, Phleum pratense)
13) )Individuals who had a habit to ingest foods claiming to effect on blood glucose level improvement , foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period.
14) Individuals who have a habit to use drug claiming to effect on blood glucose level improvement in the past 3 months.
15) Individuals who conducted hormone replacement therapy in the past 6 months or have a history of conducting hormone replacement therapy.
16) Individuals who were hospitalized and received treatment in the past 6 months, or will be hospitalized during the test period.
17) Individuals who participated in other clinical studies in the past 1 months.
18) Individuals judged inappropriate for the study by the principal.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Toshihiro
Middle name
Last name Kawama

Organization

Morinaga & Co., Ltd.

Division name

Health Science and Research Center, R&D institute

Zip code

230-8504

Address

2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama

TEL

045-571-6140

Email

t-kawama-jb@morinaga.co.jp


Public contact

Name of contact person

1st name Eriko
Middle name
Last name Saito

Organization

Morinaga & Co., Ltd.

Division name

Health Science and Research Center, R&D institute

Zip code

230-8504

Address

2-1-1, Shimodueyoshi, Tsurumi-ku, Yokohama

TEL

045-571-6140

Homepage URL


Email

e-saito-jd@morinaga.co.jp


Sponsor or person

Institute

Morinaga & Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Morinaga & Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

General Incorporated Association Crinical Research Review Center

Address

2972-8-603 Ishikawamachi Hachioji-shi, Tokyo, 192-0032, JAPAN

Tel

0426-48-4368

Email

crrctakashima@kpd.biglobe.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 12 Month 26 Day

Date of IRB

2022 Year 12 Month 21 Day

Anticipated trial start date

2023 Year 02 Month 06 Day

Last follow-up date

2023 Year 03 Month 17 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 02 Month 28 Day

Last modified on

2023 Year 08 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057442


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name